Влияние пролонгированного тестостерона ундеканоата на метаболические и гормональные параметры у мужчин с ожирением и хронической сердечной недостаточностью
https://doi.org/10.17650/2070-9781-2013-1-27-32
Аннотация
Об авторах
Н. П. Гончаров
ФГБУ ЭНЦ Минздрава России
Россия
Москва
Россия
Москва
Г. В. Кация
ФГБУ ЭНЦ Минздрава России
Россия
Москва
Россия
Москва
Л. М. Гайворонская
ГБОУ ВПО «Воронежская государственная медицинская академия им. Н.Н. Бурденко» Минздрава России
Россия
Россия
В. И. Золоедов
ГБОУ ВПО «Воронежская государственная медицинская академия им. Н.Н. Бурденко» Минздрава России
Россия
Россия
В. М. Усков
ГБОУ ВПО «Воронежская государственная медицинская академия им. Н.Н. Бурденко» Минздрава России
Россия
Россия
Список литературы
1. Wu F.C., von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217.
2. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr Rev 2003;24:313–40.
3. Jones R.D., Nettleship J.E., Kapoor D. et al. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005;5:141–54.
4. Shabsigh R., Rajfer J., Aversa A. et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60:1087–92.
5. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005;96:67M–72M.
6. Corona G., Forti G., Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11:193–9.
7. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23–32.
8. Yassin A.A., Saad F., Gooren L.J. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008;40:259–64.
9. Corona G., Mannucci E., Forti G., Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587–98.
10. Khaw K.T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694–701.
11. Shores M.M., Moceri V.M., Gruenewald D.A. et al. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 2004;52:2077–81. 12. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660–5.
12. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008 Jan;93(1):68–75. Epub 2007 Oct 2.
13. Maggio M., Lauretani F., Ceda G.P. et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249–54.
14. Tibblin G., Adlerberth A., Lindstedt G., Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996;45:1605–9.
15. Malkin C.J., Pugh P.J., Morris P.D. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821–5.
16. Corona G., Monami M., Rastrelli G. et al. Testosterone and metabolic syndrome: a metaanalysis study. J Sex Med 2011;8:272–83.
17. Brand J.S., van der Tweel I., Grobbee D.E. et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011;40:189–207.
18. Goncharov N.P., Katsya G.V., Chagina N.A. Three definitions of the metabolic syndrome applied to a sample of obese men and their relation with serum testosterone. Aging Male 2008;11(3):118–22
19. Kalme T., Seppala M., Qiao Q. et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005;90:1550–6.
20. Kupelian V., Page S.T., Araujo A.B. et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843–50.
21. Кация Г.В., Гончаров Н.П., Чагин а Н.А. Нарушение баланса стероидных гормонов при ожирении и метаболическом синдроме у мужчин моложе 40 лет. Пробл эндокринол 2011;57(4):7–12
22. Muller M., Grobbee D.E., den Tonkelaar I. et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618–23.
23. Saad F., Gooren L.J. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011; 2011. pii: 471584. doi: 10.1155/2011/471584. Epub 2010 Aug 10.
24. Traish A.M., Kypreos K.E. Testosterone and cardiovascular disease: An old idea with modern clinical implications. Atherosclerosis 2011 Feb;214(2):244-8. doi: 10.1016/j. atherosclerosis. 2010.08.078.
25. Kaplan S.A., Meehan A.G., Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524–7; discussion 1527–8.
26. Allan C.A., Strauss B.J., Burger H.G. et al. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med J Aust 2006;185:424–7.
27. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226–34.
28. Allan C.A., Strauss B.J., McLachlan R.I. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007;19:448–57.
29. Mohr B.A., Bhasin S., Link C.L. et al. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155:443–52.
30. Rodriguez A., Muller D.C., Metter E.J. et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568–72.
31. Svartberg J., von Muhlen D., Sundsfjord J., Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004;19:657–63.
32. Roberge C., Carpentier A.C., Langlois M.F. et al. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 2007;293:E1465–78.
33. Krug A.W., Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008;51:1252–8.
34. Catena C., Lapenna R., Baroselli S. et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457–63.
35. Stas S., Whaley-Connell A., Habibi J. et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the reninangiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773–80.
36. Гончаров Н.П., Колесникова Г.С., Бутров а С.А. Количественные и качественные параметры надпочечникового стероидогенеза у женщин репродуктивного возраста, страдающих ожирением. Пробл эндокринол 2008;6:16–21.
37. Hannemann A., Meisinger C., Bidlingmaier M. et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011;164:751–8.
38. Briet M., Schiffrin E.L. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011;13:163–72.
39. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776–83.
40. Vinson G.P., Coghlan J.P. Expanding view of aldosterone action, with an emphasis on rapid action. Clin Exp Pharmacol Physiol 2010;37:410–6.
41. Caprio M., Feve B., Claes A. et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. The FASEB Journal 2007;21:2185–94.
42. Vermeulen A., Verdonck L., Kaufman J.M. A clinical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
43. Hintikka J., Niskanen L., Koivumaa-Honkanen H. et al. Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 2009;6:2049–57.
44. Shores M.M., Kivlahan D.R., Sadak T.I. et al. A randomized, double-blind, placebocontrolled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:1009–16.
45. Heinemann L.A. Aging Males’ Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005;28:34–8.
46. Moore C., Huebler D., Zimmermann T. et al. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80–7.
47. Daig I., Heinemann L.A., Kim S. et al. The Aging Males’ Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003;1:77.
48. Saad F., Aversa A., Isidori A.M. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.
49. Caminiti G., Volterrani M., Iellamo F. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a doubleblind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919–27.
50. Malkin C.J., Channer K.S., Jones T.H. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2011;17:262–8.
51. Jones T.H., Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318–27.
52. Jones T.H., Arver S., Behre H.M. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37.
53. Kau M.M., Lo M.J., Wang S.W., Tsai S.C. et al. Inhibition of aldosterone production by testosterone in male rats. Metabolism 1999;48:1108–14.
54. Heufelder A.E., Saad F., Bunck M.C., Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with
55. newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726–33.
56. Awersa A., Bruzziches R., Francomano D. et al. Effects testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-age men with late-onset hypogonadism and metabolic syndrome: results from 24-month, randomized, double-blin d, placebo-controlled study. J Sex Med 2010;7:3495–503.
Рецензия
Для цитирования:
Гончаров Н.П., Кация Г.В., Гайворонская Л.М., Золоедов В.И., Усков В.М. Влияние пролонгированного тестостерона ундеканоата на метаболические и гормональные параметры у мужчин с ожирением и хронической сердечной недостаточностью. Андрология и генитальная хирургия. 2013;14(1):27-32. https://doi.org/10.17650/2070-9781-2013-1-27-32
For citation:
Goncharov N.P., Katsya G.V., Gaivoronskaya L.M., Zoloedov V.I., Uskov V.M. Research effects of Testosterone undecanoate administration on metabolic and hormonal parameters at men with an obesity and a chronic heart failure. Andrology and Genital Surgery. 2013;14(1):27-32. (In Russ.) https://doi.org/10.17650/2070-9781-2013-1-27-32
Просмотров: 713
Послать статью по эл. почте 